期刊
EXPERIMENTAL CELL RESEARCH
卷 329, 期 1, 页码 110-115出版社
ELSEVIER INC
DOI: 10.1016/j.yexcr.2014.07.004
关键词
Mismatch repair; Synthetic lethality; Drug resistance; Therapeutics
资金
- Barts and The London Charity, Cancer Research UK, Wellbeing of Women
- Medical Research Council
- Medical Research Council [MR/K001620/1] Funding Source: researchfish
- Wellbeing of Women [RG1629] Funding Source: researchfish
- MRC [MR/K001620/1] Funding Source: UKRI
The DNA Mismatch repair (MMR) pathway is critical for the maintenance of genomic stability. It is primarily responsible for the recognition and repair of mismatches that occur during DNA replication, but accumulating evidence suggest additional non-canonical roles for MMR proteins. MMR deficiency is a common feature of many tumor types. Germline mutations in MMR genes gives rise to the familial disorder, Lynch syndrome, which is associated with an increased predisposition to numerous cancers, including colorectal and endometrial. MMR deficiency has been associated with resistance to a wide range of standard therapeutic agents such as methylating agents, platinum compounds and fluoropyrimidine agents. Therefore, there is critical clinical need to identify new therapies for these resistant tumors. Recent studies, focussing on synthetic lethal interactions with MMR loss and emerging data identifying novel regulators of MMR may enable more successful treatment for MMR deficient patients. This review focuses on MMR loss in cancer and how exploiting both the canonical and non-canonical roles of MMR proteins may aid future therapeutic strategies. (C) 2014 Elsevier Inc All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据